Autopsy report · NCT07395258

A Study to Test Different Doses of BI 3923948 Alone and in Combination With an Anti-PD-1 Antibody in People With Different Types of Advanced Cancer (Solid Tumors)

“Temporary enrolment hold as a precautionary measure following a safety event in a related trial”

The sponsor’s own words in the registry.

Life of this trial

• Registered 2 months before it started.
• Suspended: paused, and may or may not restart.
• 60 participants planned (an estimate, not an actual count).

Vital statistics

Status

Suspended

Phase

Phase 1

Sponsor

Boehringer Ingelheim

Sponsor type

Industry

Conditions

Solid Tumors

Interventions

BI 3923948; Ezabenlimab

Participants

60 (planned, not actual)

Sites

2

Countries

United States

Trials that died the same way

• A Study to Test Different Doses of BI 1831169 Alone and in Combination With an Anti-PD-1 Antibody in People With Different Types of Advanced Cancer (Solid Tumors)
  “Sponsor decision - temporary enrolment hold as a precautionary measure following a safety event.” (81% match in meaning)
• A Trial in Painful Diabetic Peripheral Neuropathy With GRT3983Y
  “Trial was stopped due to difficult enrolment” (58% match in meaning)
• Study of Tazemetostat in Adults With Follicular Lymphoma Previously Treated With at Least Two Therapies
  “Withdrawn prior to enrolment after review of updated safety data” (56% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.